Skip to main content

Table 2 Subject demographics and clinical characteristics

From: Demographic profile, clinical features, and outcome of peripapillary subretinal hemorrhage: an observational study

 

Group 1

Group 2

Group 3

Total

p# value

PSH

PSH + IPH

PSH + IPH + VH

(na = 4)

(n = 17)

(n = 17)

(n = 38)

Age (years)

     

Mean ± SD

18.75 ± 7.50

22.12 ± 8.89

18.29 ± 5.60

20.05 ± 7.47

ptotal

0.315

Range

15–30

10–39

11–31

10–39

 

Gender, N (%)

     

Male

3 (75%)

2 (11.8%)

7 (41.2%)

12 (31.6%)b

 

Female

1 (25%)

15 (88.2%)

10 (58.8%)

26 (68.4%)

 

Risk factor

1

3

6

10

 

Male

1

1

2

4c

 

Female

0

2

4

6

 

Myopia (Diopters)

     

Mean ± SD

2.88 ± 1.09

3.28 ± 1.39

3.57 ± 2.24

3.37 ± 1.77

ptotal

0.758

Range

2.00–4.25

1.75–7.00

1.25–9.00

1.25–9.00

  

BCVA (LogMAR)

     

Visit 0 (Mean ± SD)

−0.02 ± 0.11

0.13 ± 0.17

0.46 ± 0.50

0.26 ± 0.39

ptotal

0.012

p12

0.16

p13

0.01

p23

0.05

Endpoint (Mean ± SD)

−0.06 ± 0.08

−0.03 ± 0.09

0.01 ± 0.06

−0.02 ± 0.08

ptotal

0.189

Duration of absorption (months)

     

Mean ± SD

2.00 ± 0.82

2.53 ± 1.07

3.59 ± 1.42

2.95 ± 1.33

ptotal

0.018

p13 < 0.05

p12 > 0.05

p23 > 0.05

Range

1–3

1–4

2–6

1–6

  

Recurrence

0

0

0

0

 
  1. BCVA best-corrected visual acuity, IPH intrapapillary hemorrhage, PSH peripapillary subretinal hemorrhage, SD standard deviation, VH vitreous hemorrhage
  2. #: ptotal: p value of comparison among all groups; p12: p value of comparison between Group 1 and Group 2; p13: p value of comparison between Group 1 and Group 3; p23: p value of comparison between Group 2 and Group 3
  3. aAffected eyes
  4. bOne male both eyes affected
  5. cBilateral eyes affected man, his right eye in Group 1, his left eye in Group 3